Prestige Consumer Healthcare Inc.
PBHAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jan 30, 2026 | Jefferies | Keith Devas | $66.00(+3%) | $64.18 | TheFly |
| Oct 27, 2025 | Jefferies | $71.00(+15%) | $61.95 | TheFly | |
| Nov 5, 2024 | Canaccord Genuity | SUsan Anderson | $86.00(+15%) | $74.58 | StreetInsider |
| Jun 21, 2024 | D.A. Davidson | Linda Bolton Weiser | $93.00(+37%) | $68.13 | StreetInsider |
| Nov 17, 2022 | Canaccord Genuity | $71.00(+22%) | $58.35 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Canaccord Genuity | maintain | Buy | Nov 6, 2026 |
| Canaccord Genuity | maintain | Buy | May 15, 2026 |
| Oppenheimer | downgrade | Outperform →Perform | May 14, 2026 |
| Oppenheimer | maintain | Outperform | May 7, 2026 |
| Jefferies | maintain | Hold | Feb 2, 2026 |
| Canaccord Genuity | maintain | Buy | Nov 7, 2025 |
| Jefferies | maintain | Hold | Oct 27, 2025 |
| Oppenheimer | maintain | Outperform | Oct 21, 2025 |
| Canaccord Genuity | maintain | Buy | Aug 8, 2025 |
| RBC Capital | maintain | Sector Perform | Mar 21, 2025 |
| Oppenheimer | maintain | Outperform | Feb 13, 2025 |
| Canaccord Genuity | maintain | Buy | Feb 7, 2025 |
| DA Davidson | maintain | Buy | Feb 7, 2025 |
| DA Davidson | maintain | Buy | Nov 11, 2024 |
| DA Davidson | maintain | Buy | Aug 28, 2024 |
| DA Davidson | maintain | Buy | Aug 9, 2024 |
| Canaccord Genuity | maintain | Buy | Aug 9, 2024 |
| DA Davidson | upgrade | Neutral →Buy | Jun 21, 2024 |
| Canaccord Genuity | maintain | Buy | May 21, 2024 |
| DA Davidson | maintain | Neutral | May 16, 2024 |
| DA Davidson | maintain | Neutral | Jun 26, 2023 |
| DA Davidson | maintain | Neutral | May 8, 2023 |
| RBC Capital | maintain | Sector Perform | Mar 17, 2023 |
| Oppenheimer | maintain | Outperform | Feb 17, 2023 |
| Oppenheimer | maintain | Outperform | Jan 13, 2023 |
Earnings History
Next report: Feb 4, 2027 · EPS est. $1.23| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $1.13 | $1.07 | $336.3M | $329.1M |
| Aug 6, 2026 | $0.98 | $0.89 | $265.7M | $253.0M |
| May 13, 2026 | $1.23 | $1.39 | $281.6M | $293.6M |
| Feb 5, 2026 | $1.14 | $1.16 | $283.4M | $282.2M |
| Nov 6, 2025 | $1.07 | $0.97 | $274.1M | $294.2M |
| Aug 7, 2025 | $0.95 | $1.01 | $249.5M | $275.0M |
| May 8, 2025 | $1.32 | $1.30 | $296.8M | $270.4M |
| Feb 6, 2025 | $1.22 | $1.16 | $290.3M | $289.8M |
News
Premium Brands TSE: PBH maintained its outlook and expressed confidence in its 2027 growth targets, even as weaker foodservice demand and a delayed procurement initiative at its Stampede business contributed to a third-quarter shortfall against internal plans.
Prestige Consumer Healthcare NYSE: PBH reported fiscal second-quarter revenue growth of 22.7%, driven by its recent acquisitions, but lowered its full-year outlook as production disruptions continued to constrain its Clear Eyes brand.
Prestige Consumer Healthcare Inc. ( PBH ) Q2 2027 Earnings Call November 5, 2026 8:30 AM EST Company Participants Philip Terpolilli - Director of Investor Relations Ron Lombardi - Chairman, President & CEO Christine Sacco - CFO & COO Conference Call Participants Keith Devas - Jefferies LLC, Research Division Susan Anderson - Canaccord Genuity Corp., Research Division Rupesh Parikh - Oppenheimer & Co. Inc., Research Division David Shakno - William Blair & Company L.L.C., Research Division Mitchel…
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TARRYTOWN, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.
During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. We initiated a position in IRadimed at the start of the quarter, replacing Talkspace after it was acquired.
On October 23, 2026, Prestige Consumer Healthcare Inc (PBH) shares fell 3.4%, closing at $47.80. The stock has experienced significant volatility, with a 52-wee
PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challenges.
TARRYTOWN, N.Y., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2027 second quarter and first half earnings release on Thursday, November 5, 2026 before the opening of the market.
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
While 63% say women are more comfortable discussing intimate wellness than five years ago, new research reveals a gap between cultural progress and personal comfort TARRYTOWN, N.Y., Sept. 30, 2026 /PRNewswire/ -- Women may be talking more openly about intimate health and wellness, but that does not necessarily mean the discomfort has disappeared.
Premium Brands Holdings Co. (TSE: PBH - Get Free Report) hit a new 52-week low during trading on Wednesday. The company traded as low as C$75.25 and last traded at C$75.55, with a volume of 13629 shares changing hands. The stock had previously closed at C$75.79. Analysts Set New Price Targets PBH has been the subject
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m.
National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting stress-related behaviors that extend into bedtime. NFL legends Ronde & Tiki Barber join DenTek to encourage fans to recognize when football stress may be affecting more than just game day.
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?